MESOTHELIOMA STUDIES
Mates Phase 111 trial of the antiangeogenic agent thalidomide in patients with malignant pleural mesothelioma after first line chemotherapy Contact: Robyn 99265034
OVARIAN STUDIES
Extend A randomised parallel group open label acive controlled multicentre phase 111 trial of Patupilone versus pegylated liposomal doxorubicin( Doxil/caelyx) in taxane/ platinum refactory/resistant patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancer. Contact: Jo 99265079 Scotroc A Prospective, Multicentre, Randomised Trial of Carboplatin Flat Dosing vs. Intrapatient Dose Escalation as First Line Chemotherapy of Ovarian, Fallopian Tube and Primary Peritoneal Cancers Contact: Rob 99265686 Tripod A single arm phase 11 trial of intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers. Contact: Laurie 99265657
Icon 7 A randomised, two-arm, multi-centre Gynecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer. Contact: Robyn 99265686 A Phase 1- 2 open label adaptive randomised study of liposomal doxorubicin with or without M200(Volociximab) for the treatment of subjects with advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer that have relapsed after prior therapy with a platinum /taxane based chemotherapy Contact: Sally 99265049
Overture Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol (Oral Dosage Form) in Combination with Carboplatin versus Carboplatin with Placebo in Patients with Platinum-Resistant or Platinum-Refractory LateStage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Contact: Laurie 99265657
BRAIN STUDIES
A phase II, open label, multi-centre, single-arm study, evaluating the efficacy of Glivec plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), receiving enzyme inducing anticonvulsant drugs (EIACDs) Contact: Robyn 99265034 A Phase 111 randomised double blind study comparing human corticotropin releasing factor(hCRF) to dexamethasone for control of symptoms associated with peritumoral brain oedema in patients with primary malignant glioma. (302) Contact : Sally/ Claire 99265049 A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated with Peritumoral Brain Edema in Patients with Malignant Brain Tumors who Require Chronic Administration of High-Dose Dexamethasone (303) Contact : Sally/ Claire 99265049
An open label extended use study of Human Corticotropin-Releasing Factor (hCRF) intended for patients who participate in the dexamethasone sparing trials NTI 0302 or NTI 0303.
Contact : Sally/ Claire 99265049
BREAST STUDIES (Adjuvant)
Soft A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer. Contact: Laurie 99265657
IBIS 2 An International Multi centre study of Tamoxifen vs Anastrozole in post menopausal women with hormone sensitive Ductal Carcinoma in situ (DCIS) Contact: Bronwyn 99265009 Poem Phase 11 trial of LHRH analogue administration during chemotherapy to reduce ovarian failure following standard adjuvant chemotherapy in early stage hormone receptor negative breast cancer. Contact: Claire 99265032 Beatrice An International multicentre open label 2 arm phase 111 trial of Adjuvant bevacizumab in triple negative breast cancer. Contact : Robyn 99265686 Beth A multicentre phase 111 randomised trial comparing trastuzumab containing regimen with and without bevacizumab as adjuvant therapy for patients with Her2 positive breast cancer Contact: Sally99265049
BREAST STUDIES (Metastatic)
Athena Open-label Study of Bevacizumab (Avastin®) plus Taxane Monotherapy or in Combination for the First-line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer Contact : Claire 99265032 Ribbon A Phase 111 multicentre randomised placebo controlled trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer. Contact: Sally 99265049
COLORECTAL STUDIES (Adjuvant)
Quazar 2 adjuvant study A Phase III International multicentre randomised study of capecitabine bevacizumab as adjuvant treatment of colon cancer. Contact: Robyn 99265686
COLORECTAL STUDIES (Metastatic)
1. Pregababolin for peripheral Neuropathy A randomised double blind placebo controlled trial of the prevention and treatment of chemotherapy induced peripheral neuropathy symptoms with advanced colorectal cancer. Contact: Laurie 99265657
2.
Sir Spheres Randomised comparative study of Folfox 6m plus Sir Spheres versus Folfox 6m alone as first line treatment in patients with non resectable liver metastases from primary colorectal cancer. Contact: Laurie 99265657
3.
A randomised multicentre phase 3 study to compare the efficacy of panitumumab in combination with chemotherapy to the efficacy of chemotherapy alone in patients with previously treated metastatic colorectal cancer Contact: Jo 99265657 Affirm A randomised multinational phase 11 study of Aflibercept and modified Folfox 6 as first line treatment in patients with metastatic colorectal cancer Contact: Sally 99265049
4.
Horizon 13 A Randomised Double blind Multicentre phase11/111 Study to compare the efficacy of AZD2171 in combination with 5 Fluorouracil, leucovorin and oxaliplatin (Folfox) to the efficacy of Bevacizumab in combination with Folfox in patients with previously untreated metastatic colorectal cancer Contact:Laurie (65657)
LUNG STUDIES (Adjuvant)
Radiant A Multicentre randomised, double blind, placebo controlled, phase 3 study of single agent Tarceva ( Erlotinib) following complete tumour resection and with or without adjuvant chemotherapy in patients with stage 1B /111A non small cell lung cancer who have EGFR positive tumours Contact : Sally 99265049
LUNG STUDIES (Stage 3)
Stimuvax A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax®® (L-BLP25 or BLP25 liposome vaccine) in non-small cell lung cancer (NSCLC) subjects with unresectable stage III disease Contact: Jo 99265079
LUNG STUDIES ( 1st line)
Sail Open label study of bevacizumab (Avastin) in combination with platinum containing chemotherapy as first line treatment of patients with advanced or recurrent non squamous non small cell lung cancer Contact: Laurie 99265657 Fight A Multicentre randomised open label phase 11 trial of tarceva in combination with gemcitabine compared to gemcitabine monotherapy as first line therapy in ECOG PS 2 patients with chemo naïve advanced NSCLC Contact : Rob 99265686 AMG 706 A Phase 3, multicentre randomised placebo controlled double blind trial of AMG 706 in combination with paclitaxel and carboplatin for advanced non small cell lung cancer Contact: Laurie 99265657
LUNG STUDIES (2nd/3rd line)
Saturn
A multicentre, double-blind randomized, phase III study to evaluate the efficacy of Tarceva™ or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented advanced or recurrent (stage IIIB and not amenable for combined modality treatment) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) who have not experienced disease progression or unacceptable toxicity during chemotherapy.
Contact: Jo 99265079 Titan A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva™ or comparator Alimta® (pemetrexed) or Taxotere® (docetaxel) in patients with histologically documented, advanced or recurrent (stage IIIb and not amenable for combined modality treatment) or metastatic (stage IV) non-small cell lung cancer who have experienced disease progression during (tolerated) platinum-based chemotherapy. Contact: Jo 99265079 Zactima Lung( Study 44) A Phase III, International, Randomised, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB – IV) Non-Small Cell Lung Cancer (NSCLC) after Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Contact : Sally/ Claire 99265049
Zactima/Alimta (Study 36) A Phase III, Randomised, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy and safety of ZD6474 (ZACTIMA™) in combination with Pemetrexed (Alimta) Versus Pemetrexed alone in Patients With Locally Advanced or Metastatic (Stage IIIB – IV) Non-Small Cell Lung Cancer (NSCLC) after failure of 1st line anti cancer therapy Contact: Sally/ Robyn 99265049
PANCREAS and BILIARY TRACT STUDIES
Espac 3
Phase III Adjuvant Trial in Pancreatic Cancer Comparing (1) 5-FU and D-L Folinic Acid versus (2) Gemcitabine
Contact: Jo 99265079 EPA Effects of fish oil containing EPA on wight loss and cachexia in pacreatic patients under going gemcitabine chemotherapy Contact: Sally 99265049 GOFORTGO Phase II Study of Fixed Dose Rate Gemcitabine-Oxaliplatin Integrated with concomitant 5FU and 3-D Conformal Radiotherapy for the treatment of Localised Pancreatic Cancer Contact : Claire 99265032 AG013736 A randomised double blind phase 3 study of Gemcitabine plus AG013736 versus Gemcitabine plus placebo for the first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer. Contact: Laurie 99265657
PROSTATE STUDIES
Study 14 A Phase 111 randomised double blind study to assess the efficacy and safety of 15mg ZD4054 versus placebo both with best supportive care in patients with hormone resistant Prostate Cancer and Bone Metastases who are pain free or mildly symptomatic Contact: Jo 99265079 Study 33 A Phase 111 randomised double blind placebo controlled study to assess the efficacy and safety of 15mg ZD4054 in combination with docetaxel in patients with metastatic hormone resistant Prostate Cancer Contact: Jo 99265079
RENAL CELL STUDIES
A randomised Trial of Temsirolimus and Sorafeib as second line therapy in patients with advanced renal cell carcinoma who have failed first line sunitinib therapy Contact: Claire 99265032